Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Venmax Drugs And Pharmaceuticals Ltd. shows no growth and profitability metrics, positioning it poorly against peers in the pharmaceuticals sector. Notably, peers like Sun Pharmaceutical Industries and Dr. Reddy's Laboratories demonstrate strong growth, profitability, and efficient operations, making them sector leaders. Venmax, with its significantly high valuation metrics and lack of profitability, appears overvalued and financially weak compared to its well-performing counterparts.
Highest revenue growth (YoY) at 8.42% and strong ROE of 16.13%.
Consistent profitability with an ROE of 21.76% and a PE ratio of 15.5, indicating good value.
Strong revenue growth of 13.28% and low PE ratio of 23.73, making it a solid value pick.